The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs.
Identifieur interne : 000432 ( PubMed/Corpus ); précédent : 000431; suivant : 000433The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs.
Auteurs : Y S Shin ; J Y Seo ; S H Oh ; J H Kim ; S T Kim ; Y B Park ; H S MoonSource :
- Oral diseases [ 1601-0825 ] ; 2014.
English descriptors
- KwdEn :
- Animals, Bone Morphogenetic Protein 2 (pharmacology), Bone Substitutes, Catechin (analogs & derivatives), Catechin (pharmacology), Dental Implants, Dental Prosthesis Design, Dogs, Guided Tissue Regeneration, Periodontal, Hydroxyapatites, Osteogenesis (drug effects), Recombinant Proteins (pharmacology), Titanium, Transforming Growth Factor beta (pharmacology).
- MESH :
- chemical , analogs & derivatives : Catechin.
- chemical , pharmacology : Bone Morphogenetic Protein 2, Catechin, Recombinant Proteins, Transforming Growth Factor beta.
- drug effects : Osteogenesis.
- Animals, Bone Substitutes, Dental Implants, Dental Prosthesis Design, Dogs, Guided Tissue Regeneration, Periodontal, Hydroxyapatites, Titanium.
Abstract
The purpose was to evaluate the effect of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2)-/epigallocatechin-3-gallate (EGCG)-coated biphasic calcium phosphate (BCP) and titanium barrier membrane on dehiscence defects in dogs.
DOI: 10.1111/odi.12109
PubMed: 23651333
Links to Exploration step
pubmed:23651333Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs.</title>
<author><name sortKey="Shin, Y S" sort="Shin, Y S" uniqKey="Shin Y" first="Y S" last="Shin">Y S Shin</name>
<affiliation><nlm:affiliation>Department of Conservative Dentistry, Oral Science Research Center, Yonsei University College of Dentistry, Seoul, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Seo, J Y" sort="Seo, J Y" uniqKey="Seo J" first="J Y" last="Seo">J Y Seo</name>
</author>
<author><name sortKey="Oh, S H" sort="Oh, S H" uniqKey="Oh S" first="S H" last="Oh">S H Oh</name>
</author>
<author><name sortKey="Kim, J H" sort="Kim, J H" uniqKey="Kim J" first="J H" last="Kim">J H Kim</name>
</author>
<author><name sortKey="Kim, S T" sort="Kim, S T" uniqKey="Kim S" first="S T" last="Kim">S T Kim</name>
</author>
<author><name sortKey="Park, Y B" sort="Park, Y B" uniqKey="Park Y" first="Y B" last="Park">Y B Park</name>
</author>
<author><name sortKey="Moon, H S" sort="Moon, H S" uniqKey="Moon H" first="H S" last="Moon">H S Moon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:23651333</idno>
<idno type="pmid">23651333</idno>
<idno type="doi">10.1111/odi.12109</idno>
<idno type="wicri:Area/PubMed/Corpus">000432</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000432</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs.</title>
<author><name sortKey="Shin, Y S" sort="Shin, Y S" uniqKey="Shin Y" first="Y S" last="Shin">Y S Shin</name>
<affiliation><nlm:affiliation>Department of Conservative Dentistry, Oral Science Research Center, Yonsei University College of Dentistry, Seoul, Korea.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Seo, J Y" sort="Seo, J Y" uniqKey="Seo J" first="J Y" last="Seo">J Y Seo</name>
</author>
<author><name sortKey="Oh, S H" sort="Oh, S H" uniqKey="Oh S" first="S H" last="Oh">S H Oh</name>
</author>
<author><name sortKey="Kim, J H" sort="Kim, J H" uniqKey="Kim J" first="J H" last="Kim">J H Kim</name>
</author>
<author><name sortKey="Kim, S T" sort="Kim, S T" uniqKey="Kim S" first="S T" last="Kim">S T Kim</name>
</author>
<author><name sortKey="Park, Y B" sort="Park, Y B" uniqKey="Park Y" first="Y B" last="Park">Y B Park</name>
</author>
<author><name sortKey="Moon, H S" sort="Moon, H S" uniqKey="Moon H" first="H S" last="Moon">H S Moon</name>
</author>
</analytic>
<series><title level="j">Oral diseases</title>
<idno type="eISSN">1601-0825</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Bone Morphogenetic Protein 2 (pharmacology)</term>
<term>Bone Substitutes</term>
<term>Catechin (analogs & derivatives)</term>
<term>Catechin (pharmacology)</term>
<term>Dental Implants</term>
<term>Dental Prosthesis Design</term>
<term>Dogs</term>
<term>Guided Tissue Regeneration, Periodontal</term>
<term>Hydroxyapatites</term>
<term>Osteogenesis (drug effects)</term>
<term>Recombinant Proteins (pharmacology)</term>
<term>Titanium</term>
<term>Transforming Growth Factor beta (pharmacology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Catechin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Bone Morphogenetic Protein 2</term>
<term>Catechin</term>
<term>Recombinant Proteins</term>
<term>Transforming Growth Factor beta</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Osteogenesis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Bone Substitutes</term>
<term>Dental Implants</term>
<term>Dental Prosthesis Design</term>
<term>Dogs</term>
<term>Guided Tissue Regeneration, Periodontal</term>
<term>Hydroxyapatites</term>
<term>Titanium</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose was to evaluate the effect of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2)-/epigallocatechin-3-gallate (EGCG)-coated biphasic calcium phosphate (BCP) and titanium barrier membrane on dehiscence defects in dogs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23651333</PMID>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>03</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1601-0825</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>20</Volume>
<Issue>3</Issue>
<PubDate><Year>2014</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Oral diseases</Title>
<ISOAbbreviation>Oral Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs.</ArticleTitle>
<Pagination><MedlinePgn>281-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/odi.12109</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose was to evaluate the effect of Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2)-/epigallocatechin-3-gallate (EGCG)-coated biphasic calcium phosphate (BCP) and titanium barrier membrane on dehiscence defects in dogs.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In five mongrel dogs, the dehiscence bony defects around dental implants were surgically created and in total three implants were placed at edentulous ridge of which teeth had been extracted 12 weeks before. For the control group, BCP was applied to the dehiscence defect. For experimental groups, ErhBMP-2-coated BCP and ErhBMP-2-/EGCG-coated BCP were applied. The newly designed titanium barrier membrane was used to apply all the defects. The defects were evaluated histologically and histometrically after 12 weeks. The comparative statistics of the groups were obtained through Kruskal-Wallis test.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In bone-to-implant contact (BIC), bone density (BD), bone regeneration height (BRH), and bone mineralization apposition rate (BMAR), differences among groups were not found. ErhBMP-2/EGCG group appeared to have higher value. In fluorescence analysis, bone remodeling around graft material was more active in the ErhBMP-2/EGCG group.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Within the limit of this study, it is reasonable to assume that BMP-2-/EGCG-coated biphasic BCP and the newly designed titanium membrane were more beneficial in dehiscence defect healing with increased bone remodeling.</AbstractText>
<CopyrightInformation>© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shin</LastName>
<ForeName>Y S</ForeName>
<Initials>YS</Initials>
<AffiliationInfo><Affiliation>Department of Conservative Dentistry, Oral Science Research Center, Yonsei University College of Dentistry, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Seo</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Oh</LastName>
<ForeName>S H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>S T</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y"><LastName>Park</LastName>
<ForeName>Y B</ForeName>
<Initials>YB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moon</LastName>
<ForeName>H S</ForeName>
<Initials>HS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>05</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Denmark</Country>
<MedlineTA>Oral Dis</MedlineTA>
<NlmUniqueID>9508565</NlmUniqueID>
<ISSNLinking>1354-523X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055396">Bone Morphogenetic Protein 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018786">Bone Substitutes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015921">Dental Implants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006882">Hydroxyapatites</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C074950">hydroxyapatite-beta tricalcium phosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C499469">recombinant human bone morphogenetic protein-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8R1V1STN48</RegistryNumber>
<NameOfSubstance UI="D002392">Catechin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>BQM438CTEL</RegistryNumber>
<NameOfSubstance UI="C045651">epigallocatechin gallate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>D1JT611TNE</RegistryNumber>
<NameOfSubstance UI="D014025">Titanium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>D</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055396" MajorTopicYN="N">Bone Morphogenetic Protein 2</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018786" MajorTopicYN="Y">Bone Substitutes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002392" MajorTopicYN="N">Catechin</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015921" MajorTopicYN="Y">Dental Implants</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017267" MajorTopicYN="N">Dental Prosthesis Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016557" MajorTopicYN="N">Guided Tissue Regeneration, Periodontal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006882" MajorTopicYN="Y">Hydroxyapatites</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010012" MajorTopicYN="N">Osteogenesis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014025" MajorTopicYN="Y">Titanium</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ErhBMP-2</Keyword>
<Keyword MajorTopicYN="N">GBR</Keyword>
<Keyword MajorTopicYN="N">biphasic calcium phosphate</Keyword>
<Keyword MajorTopicYN="N">dehiscence defect</Keyword>
<Keyword MajorTopicYN="N">epigallocatechin-3-gallate</Keyword>
<Keyword MajorTopicYN="N">titanium barrier membrane</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>12</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>03</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>04</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>5</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>5</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23651333</ArticleId>
<ArticleId IdType="doi">10.1111/odi.12109</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000432 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000432 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= EdenteV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:23651333 |texte= The effects of ErhBMP-2-/EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23651333" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a EdenteV1
This area was generated with Dilib version V0.6.33. |